With deep ties to China, Vivace exits stealth mode with a lead cancer program, platform and $40M
It’s not unusual for investors to quietly seed a stealth biotech long enough to see if they’re on to something, then debut the company with a Series A. In Vivace Therapeutics’ case, the West Coast biotech waited for the Series B, fleshing out a lead program and a platform technology to help it stand out in a crowd of startups.
In the process, backers have expanded the syndicate to include a lineup of transpacific investors drawn to a company with roots in China as well as California, spawning a new kind of virtual company with a handful of fulltime staffers and some high-profile scientific founders with their own cross-cultural backgrounds that fit this company perfectly.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
